Cargando…
300. Long COVID in Cancer Patients: Preponderance of Symptoms in Majority of Patients Over Long Time Period
BACKGROUND: An increasing number of observational studies have reported the persistence of symptoms following recovery from acute COVID-19 disease. The long-term consequences of COVID-19 are not fully understood and there is no clear consensus on the definition of post-acute sequelae of SARS-CoV-2 i...
Autores principales: | Dagher, Hiba, Malek, Alexandre, Chaftari, Anne-Marie, Subbiah, Ishwaria M, Jiang, Ying, Lamie, Peter, Granwehr, Bruno, John, Teny, Guevara, Eduardo Yepez, Borjan, Jovan, Reyes, Cielito, Flores, Mary, Khawaja, Fareed, Pande, Mala, Ali, Norman, Rojo, Raniv, Karp, Daniel D, Hachem, Ray Y, Raad, Issam I |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644490/ http://dx.doi.org/10.1093/ofid/ofab466.502 |
Ejemplares similares
-
Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time period
por: Dagher, Hiba, et al.
Publicado: (2023) -
859. The Role of Procalcitonin in Antimicrobial De-escalation and Stewardship Program in Febrile Neutropenic Cancer Patients
por: Dagher, Hiba, et al.
Publicado: (2023) -
363. A Phase II Prospective Randomized Study to Assess Imipenem-Relebactam in the Management of Cancer Patients with Febrile Neutropenia
por: Chaftari, Anne-Marie, et al.
Publicado: (2023) -
Procalcitonin for antimicrobial stewardship among cancer patients admitted with COVID-19
por: Dagher, Hiba, et al.
Publicado: (2022) -
1636. Risk of Latent Tuberculosis Reactivation in Patients Treated with Checkpoint Inhibitors Immunotherapy Compared to Other Anti-Cancer Therapies including Hematopoietic Cell Transplantation
por: Malek, Alexandre, et al.
Publicado: (2020)